Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.

Azitra, Inc.

Azitra develops novel therapeutics to treat adverse skin conditions and disease using microbial and genetic engineering approaches for precision dermatology.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

National Institutes of Health

National Science Foundation

U.S. Department of Defense

Bios Partners

Connecticut Innovations

Godfrey Capital

KdT Ventures

Leaps by Bayer

Sahsen Ventures

Azitra Inc

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

https://lnkd.in/eb2fzkQd

Azitra Inc (NYSE American: AZTR) Announces Pricing of $10.0 Million Public Offering. Maxim Group LLC is acting as the exclusive placement agent.

Read the full press release: https://lnkd.in/eiM4dhwu

Brad Hoffman, Danny Fossey, Robert Solomon, Stephen Polsinelli

Today, we're announcing the strengthening of our IP portfolio with a newly issued US patent and three additional patent allowances globally. 

Read more here:

https://lnkd.in/eNAB7rMF

We'll be at the Foundation for Foundation for Ichthyosis & Related Skin Types, Inc. (FIRST) conference this weekend to connect with patients and share about our clinical trial for Netherton syndrome at Azitra.

#FIRSTNC24 #NethertonSyndrome

We'll be at the Society of Investigative Dermatology this Friday in Dallas presenting new data on our platform and ATR-04

This Friday, we'll be presenting new data on our platform and Netherton syndrome program at ASGCT 2024. Stop by if you'll be there! 

https://lnkd.in/e_j2riaH

Today, we’re announcing the issuance of a new patent to strengthen our IP position and bolster our platform for precision dermatology.

https://lnkd.in/eMWwZqVn

	Dec '21	Dec '22	Dec '23
net income	-8.94M -	-10.68M 19.47%	-11.28M 5.65%
depreciation and amortization	84.77K -	405.98K 378.90%	425.55K 4.82%
deferred income tax	-231.67K -	7.10K 103.07%	-28.28K 498.20%
stock based compensation	306.06K -	184.47K 39.73%	151.50K 17.87%
change in working capital	646.35K -	310.76K 51.92%	-753.43K 342.45%
accounts receivables	-37.57K -	-21.95K 41.57%	84.56K 485.21%
inventory	385.95K -	-229.04K 159.34%	-613.31K 167.78%
accounts payables	282.98K -	420.75K 48.69%	-68.68K 116.32%
other working capital	15K -	141K 840%	-156K 210.64%
other non cash items	66.81K -	1.42M 2,029.21%	4.13M 190.04%
net cash provided by operating activities	-8.07M -	-8.35M 3.50%	-7.36M 11.82%
investments in property plant and equipment	-456.01K -	-160.21K 64.87%	-318.26K 98.65%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites	-196.27K -	-176.55K 10.04%
net cash used for investing activites	-652.27K -	-336.76K 48.37%	-318.26K 5.49%
debt repayment			-7.39K -
common stock issued			5.99M -
common stock repurchased
dividends paid
other financing activites		4.13M -
net cash used provided by financing activities	992.86K -	4.13M 316.43%	5.98M 44.73%
effect of forex changes on cash
net change in cash	-7.73M -	-4.55M 41.09%	-1.70M 62.72%
cash at beginning of period	15.77M -	8.04M 48.99%	3.49M 56.58%
cash at end of period	8.04M -	3.49M 56.58%	1.80M 48.58%
operating cash flow	-8.07M -	-8.35M 3.50%	-7.36M 11.82%
capital expenditure	-456.01K -	-160.21K 64.87%	-318.26K 98.65%
free cash flow	-8.52M -	-8.51M 0.16%	-7.68M 9.74%

AZTR

COM:AZITRAINC

Azitra

Last Close

0.47

22/11 21:00

Market Cap

3.16M

Beta: -

Volume Today

128.73K

Avg: -

Preview